Mototsugu Tanaka, Haruna Miyazawa, Ryohei Terashima, Mutsuhiro Ikuma. Conditional early approval for new drug applications in Japan: Current and emerging issues. Clinical and translational science. 2023. 16. 8. 1289-1293
Mototsugu Tanaka, Mutsuhiro Ikuma, Wataru Asakura, Yasuhiro Fujiwara. The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia. Clinical Pharmacology & Therapeutics. 2022. 111. 2. 358-361
Shinobu Uzu, Shohko Sekine, Junichi Asano, Mutsuhiro Ikuma. Assessment of the impact of Japanese-specific long-term safety data on new drug approval. Clinical and Translational Science. 2021. 14. 6. 2339-2347
Mototsugu Tanaka, Mayumi Idei, Hiroshi Sakaguchi, Ryosuke Kato, Daisuke Sato, Kenji Sawanobori, Shuichi Kawarasaki, Toshiyuki Hata, Asako Yoshizaki, Miki Nakamura, et al. Achievements and challenges of the Sakigake designation system in Japan. British Journal of Clinical Pharmacology. 2021. 87. 10. 4027-4035
Mototsugu Tanaka, Mayumi Idei, Hiroshi Sakaguchi, Ryosuke Kato, Daisuke Sato, Kenji Sawanobori, Shuichi Kawarasaki, Toshiyuki Hata, Asako Yoshizaki, Miki Nakamura, et al. Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan. British Journal of Clinical Pharmacology. 2021. 87. 8. 3279-3291
Shigeru Kanaoka, Yasushi Hamaya, Shigeru Kuriyama, Mutsuhiro Ikuma, Hiroaki Mlyajima. Alteration in Fecal COX-2 mRNA Expressions Before and After Surgical or Endoscopic Resection of Colorectal Cancer and Adenoma. GASTROENTEROLOGY. 2011. 140. 5. S337-S337
米国内科学会
, 米国消化器病学会
, 日本消化器内視鏡学会
, 日本消化器病学会
, 日本内科学会
, American College of Physicians
, American Physiological Society
, American Gastroenterology Association